ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1307

Synovial Subset–Derived Baseline Serum Biomarkers Segregate Rheumatoid Arthritis Patients Into Subgroups With Distinct Serum Protein and Clinical Characteristics

A. Francesca Setiadi, Nicholas Lewin-Koh, Sarah Kummerfeld, David F. Choy, Cécile T.J. Holweg, Sally Fischer, An Song and Michael J. Townsend, Genentech, South San Francisco, CA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: biomarkers and rheumatoid arthritis, treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects II: Predictors of Disease Course in Rheumatoid Arthritis - Treatment Approaches

Session Type: Abstract Submissions (ACR)

Background/Purpose: Rheumatoid arthritis (RA) is a heterogeneous disease. Predictive biomarkers have the potential to enhance treatment effectiveness by enabling identification of likely responders to a specific therapy.1,2 Our previous analysis of RA synovium showed the existence of 3 large subsets characterized by gene expression signatures suggestive of lymphoid, myeloid, or fibroid biology.3 In the present study, we demonstrated the ability of serum proteins produced by genes selected from those signatures to recapitulate the segregation of patients into these subsets.

Methods: Several protein biomarker candidates were selected based on differential gene expression in 1 RA synovial subset versus the others and on detectability in serum. Quantitative immunoassay methods were used to measure these proteins in baseline serum from 3 biologic-naive RA cohorts: Cohort 1 (cross-sectional natural history cohort, n = 197), SERENE4 (n = 412), and TOWARD5 (n = 526). Levels of serum proteins were also compared between Cohort 1 patients and healthy controls (n = 30). Serum protein data were used to cluster patients and proteins. Patients were clustered into a specified number of groups using Partitioning Around Medoids (PAM), whereas proteins were clustered hierarchically. Each clinical characteristic of patients in each biomarker group was compared to the respective characteristic in all other groups within the same cohort using the Wilcoxon rank-sum test of each pair.

Results: Analysis of baseline serum biomarker levels in Cohort 1 showed that MMP1, MMP3, MMP9, TIMP3, TIMP4, CXCL13, IL8, CCL2, CCL13, CXCL10, and sICAM1 were elevated compared to those in healthy controls (p < 0.0001). These analytes had a wide dynamic range in all RA cohorts analyzed. The patient populations within each RA cohort segregated reproducibly into 3 groups, named by the characteristics of the serum proteins in each group: Protease, Chemokine, and Low Inflammatory. The 2 inflammatory groups (Protease and Chemokine) were dominated by serum biomarkers related to lymphoid and myeloid biology, respectively (Table 1). The third group generally displayed lower levels of inflammatory proteins, CRP, and ESR and was less often rheumatoid factor positive. This group likely corresponded to the synovial fibroid subset. The clinical characteristics of each biomarker group are summarized in Table 2.

Conclusion: We have identified serum biomarkers that segregate groups of patients associated with lymphoid and myeloid subtype–derived biomarkers in 3 large RA cohorts. These subpopulations of RA patients with distinct pathobiology can possibly demonstrate differential clinical response to treatments that target different inflammatory mediators. In addition, a low-inflammatory group was observed in all cohorts analyzed. This group is less likely to respond well to current biologic anti-inflammatory therapy.


Disclosure:

A. F. Setiadi,

Roche Pharmaceuticals,

1,

Roche Pharmaceuticals,

3;

N. Lewin-Koh,

Genentech and Biogen IDEC Inc.,

3;

S. Kummerfeld,

Genentech and Biogen IDEC Inc.,

3;

D. F. Choy,

Genentech and Biogen IDEC Inc.,

3;

C. T. J. Holweg,

Genentech and Biogen IDEC Inc.,

3;

S. Fischer,

Genentech and Biogen IDEC Inc.,

3;

A. Song,

Genentech and Biogen IDEC Inc.,

3;

M. J. Townsend,

Roche Pharmaceuticals,

1,

Genentech and Biogen IDEC Inc.,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/synovial-subset-derived-baseline-serum-biomarkers-segregate-rheumatoid-arthritis-patients-into-subgroups-with-distinct-serum-protein-and-clinical-characteristics/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology